Silexion Therapeutics Corp (NASDAQ:SLXN) Financings
Financings
| Raise | Date |
|---|---|
| Ordinary shares on exercise of series E warrants Announced: US$837,366 · US$0.2603 a share · Warrants at US$0.2603 · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital for general corporate purposes | Sep 29, 2026 |
| Public offering of ordinary shares Closed: US$2.5M raised · US$0.65 a share · Warrants at US$0.65 for 60 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Strengthen the balance sheet, support the Phase 2/3 trial of SIL204 and support Nasdaq continued listing compliance | Aug 14, 2026 |
| Public offering of ordinary shares (or ordinary share equivalents) with series A and series B warrants Announced: US$6M · US$4 a share · Warrants at US$4 for 60 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Advance pre-clinical studies and general corporate purposes | Sep 11, 2025 |
| Warrant exercise of ordinary shares on exercise of warrants Announced: about US$1.8M · US$11.57 a share · Warrants at US$11.32 for 24 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital for general corporate purposes | Aug 1, 2025 |
| Warrant exercise of ordinary shares on exercise of outstanding warrants Announced: about US$3.3M · US$1.35 a share · Warrants at US$1.5 for 24 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital for general corporate purposes | Jan 29, 2025 |
| Public offering of ordinary shares (or ordinary share equivalents) and warrants Announced: about US$5M · US$1.35 a share · Warrants at US$1.35 for 60 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Advance pre-clinical studies and general corporate purposes | Jan 15, 2025 |